PRE - הכנסה תפעולית לפני ניכוי פחת prenetics.com

Prenetics Global (PRE) automates genome sequencing using AI and robotics while maintaining expert medical oversight. Revenues are based on the sale of CircleDNA tests in Europe and Asia. Growth relies on early cancer diagnosis supported by stable capital. The change in EBITDA demonstrates financial resilience to volatility, with the indicator currently standing at 0.00.
Prenetics (PRE) - פילוחי מדדים ודוחות פיננסיים

Assessing the operational strength of assets requires analyzing a business's ability to generate cash flow before interest and taxes, which reflects the efficiency of core processes through the EBITDA metric. For Prenetics Global (PRE), this indicator confirms the monetization of patented diagnostic solutions and the high barrier to entry in the biodata niche, demonstrating the company's fundamental resilience in the face of regulatory hurdles.